Advanced methods and systems for treating cell proliferation disorders
AssigneesImmunolight, LLC, Duke University
InventorsFrederic A. Bourke, Jr., Tuan Vo-Dinh
Life of this patent
Estimating the term…
Loading patent…
AssigneesImmunolight, LLC, Duke University
InventorsFrederic A. Bourke, Jr., Tuan Vo-Dinh
Estimating the term…
The present invention relates to methods for treating cell proliferation disorders comprising: (1) administering to the subject at least one activatable pharmaceutical agent that is capable of activation by a simultaneous two photon absorption event and of effecting a predetermined cellular change when activated; (2) administering at least one plasmonics-active agent to the subject, and (3) applying an initiation energy from an initiation energy source to the subject, wherein the plasmonics-active agent enhances or modifies the applied initiation energy, such that the enhanced or modified initiation energy activates the activatable pharmaceutical agent by the simultaneous two photon absorption event in situ, thus causing the predetermined cellular change to occur, wherein said predetermined cellular change treats the cell proliferation related disorder; and the use of plasmonics enhanced photospectral therapy (PEPST) and exiton-plasmon enhanced phototherapy (EPEP) in the treatment of various cell proliferation disorders, and the PEPST and EPEP agents and probes; a kit and a computer implemented system for performing the method; a pharmaceutical composition useful in the method; and a method for causing an autovaccine effect in a subject using the method.
A pharmaceutical composition for treating a cell proliferation disorder, comprising:
A pharmaceutical composition for treating a cell proliferation disorder, comprising:
Dependencies are inferred from the claim text.